Description |
NOS-IN-3 (Compound 9a) is a potent, selective, imidamide derived NOS inhibitor with an IC50 against iNOS of 4.6 µM, without inhibiting eNOS. NOS-IN-3 has little toxicity and can be studied in the treatment of inducible isoform involved diseases, such as septic shock[1].
|
Related Catalog |
|
Target |
IC50: 4.6 µM (iNOS), > 1000 µM (nNOS)[1]
|
In Vitro |
NOS-IN-3 (Compound 9a) shows high iNOS selectivity without eNOS inhibition activity [1]. NOS-IN-3 (0-100 µM, 30 min) has little toxicity[1]. Cell Viability Assay[1] Cell Line: HUVECs Concentration: 10, 20, 50, 100, 500 µM Incubation Time: 30 min Result: Had little toxicity, only at the concentration above 100 µM, the cell viability was significantly (approximately 20%) reduced.
|
References |
[1]. Fabio Arias, et al. Bioactive imidamide-based compounds targeted against nitric oxide synthase. Bioorg Chem. 2022 Feb 2;120:105637.
|